1	Genetic and non-genetic clonal diversity in cancer evolution				
2					
3 4					
5	uthors: James R.M. Black ^{1,2} and Nicholas McGranahan ^{1,2†}				
6 7 8 9	 Cancer Genome Evolution Research Group, University College London Cancer Institute, University College London, UK Cancer Research UK Lung Cancer Center of Excellence, University College London Cancer Institute, Paul O'Gorman Building, London, UK 				
10					
11					
12	[†] email: <u>nicholas.mcgranahan.10@ucl.ac.uk</u>				
13					
14					
15					
16					
17					
18					
19 20					
20					
22					
23					
24					
25					
26 27					
27					
20 29					
30					
31					
32					
33					
34 35					
36					
37					
38					
39					
40					
41 42					
43					

44	Abstract
45 46	The observation and analysis of intra- tumour heterogeneity (ITH), particularly
47	in genomic studies, has advanced our understanding of the evolutionary forces that shape
48	cancer growth and development. However, only a subset of the variation observed in a single
49	tumour will have an impact on cancer evolution, highlighting the need to distinguish between
50	functional and non- functional ITH. Emerging studies highlight a role for the cancer
51 52	epigenome, transcriptome and immune microenvironment in functional ITH. Here, we consider the importance of both genetic and non- genetic ITH and their role in tumour
52 53	evolution and present the rationale for a broad research focus beyond the cancer genome.
54	Systems- biology analytical approaches will be necessary to outline the scale and importance
55	of functional ITH. By allowing a deeper understanding of tumour evolution this will, in time,
56	encourage development of novel therapies and improve outcomes for patients.
57	
58	
59	
60	
61	
62 63	
63 64	
65	
66	
67	
68	
69	
70	
71	
72	
73	
74 75	
76	
77	
78	
79	
80	
81 82	
82	
84	
85	
86	
87 88	
00 89	
90	

91 Introduction

92

In 1859, in his seminal text *On the Origin of Species*, Charles Darwin described a theory of branching evolution by natural selection, based on observations of incredible diversity of phenotypes amongst animals¹. At the time, the mechanisms underpinning such diversity, including genetic recombination and mutation, were unknown, but such were the strength of his deductions about the function of these variations that this theory remains in the scientific mainstream today.

99 Cancer is also an evolutionary process^{2,3}, and it was the observation of phenotypic 100 heterogeneity within tumours that led Nowell to hypothesise that Darwinian clonal evolution 101 underpinned their development². Since then, 'intra-tumour' heterogeneity (ITH), describing 102 diversity within individual tumours, has been defined at multiple different levels, including 103 single point mutations, somatic copy number alterations (SCNAs), epigenetic and 104 transcriptomic changes influencing gene expression, the antitumour immune response and 105 other features of the tumour microenvironment.

An important task that remains is to distinguish between 'functional' variation, 106 107 conferring a fitness effect that brings about an important change in tumour phenotype, from 108 'non-functional' variation⁴ (Figure 1). Indeed, the extent to which ITH is a result of the stochastic accumulation of mutations following the acquisition of founding 'driver' events, 109 110 rather than the result of continual clonal evolution and selection through time and space remains an open scientific question and a topic of debate⁵. It is likely that the true extent of 111 112 selection during cancer evolution varies both between cancer types, and within individual 113 cancers of the same type (Box 1).

114 This Review will explore what is known about functional and non-functional ITH in 115 cancer, outlining unresolved areas of debate that warrant further study. It will address the 116 diverse causes of ITH and how this might impact cancer treatment and prognosis. The advent 117 of high throughput multi-omics has increased our understanding of the interplay between 118 different cellular processes that contribute to ITH⁶. In order to appreciate in full the 119 importance of ITH in cancer, we must interrogate more than just mutations, SCNAs, or gene 120 expression in isolation; rather, we must seek to link all factors that may influence tumour 121 phenotype. With a systems-biology lens such as this, we may gain the resolution required to 122 better understand cancer evolution and comprehend its origins and vulnerabilities. 123

- 124 **ITH and evolution**
- 125

24 <u>1111 and evolution</u> 25

Cancer develops through clonal evolution^{2,3}. Genetic variation acts as a primary
 substrate for this evolution. This arises through different mechanisms of genomic instability,
 including endogenous and exogenous processes that generate point mutations, as well as
 chromosomal instability (CIN)^{7,8}.

130 Early studies of tumour heterogeneity developed the notion of cancer as an 131 evolutionary, as well as a genetic, disease. Interphase fluorescence in-situ hybridisation and 132 karyotyping of metaphase chromosomes in the 1990s demonstrated the presence of multiple clones within a tumour^{9,10}. Comparative genomic hybridisation microarray analysis enabled 133 134 accurate characterisation of the copy-number profiles of cancer clones and expanded on these 135 findings. For example, Navin and colleagues classified breast tumours as either 136 'monogenomic', containing a population of near-homogeneous tumour cells with analogous 137 genomic profiles, or 'polygenomic', containing subpopulations or 'clones' with distinct 138 genomic profiles, and demonstrated that clones in polygenomic tumours were descended 139 from a common ancestor by branched evolution¹¹. The advent of next-generation sequencing 140 has enabled this to be characterised with finer granularity. In a seminal study in 2012,

141 Gerlinger and colleagues performed multi-region whole-exome sequencing on tumour

samples from a cohort of patients with renal cell carcinoma to describe heterogeneity in

143 putative driver mutations within the same tumour, and ongoing branched evolution over 144 time¹².

Since these early observations, a central focus of research has been to distil functional 145 146 from non-functional somatic variation and to characterise the strength of the evolutionary 147 forces that shape tumour development over time. However, the extent to which cancer is 148 under continuous selection during its development is a contentious topic in the field, echoing a long-standing debate in evolutionary biology¹³. Observed differences between parts of the 149 same tumour do not themselves indicate the presence of competing subclones which are 150 under selection. The accumulation of random somatic alterations over time means that 151 152 genotypes will diverge even in the absence of selection pressures. As such, some studies have 153 suggested that a subset of tumours may evolve neutrally following the acquisition of 154 necessary driver events^{14–18}.

Low ITH of driver events, potentially indicative of selective 'clonal sweeps' of certain phenotypes early in tumour evolution, is well-described in multiple cancer types^{19–23}. Conversely, other studies have highlighted the presence of subclonal driver mutations in cancer genes, whereby only a subset of cancer cells, or clones, harbour functional somatic events assumed to confer a fitness advantage^{24–29}.

161 Methods for evaluating ITH

160

162

Accurately recapitulating the evolutionary history of a tumour from a genomic snapshot, typically provided at a single time point, and frequently from a single part of a tumour, can be problematic. Despite consensus that one size may not fit all where tumour evolution is concerned, non-uniform terminology and methods of analysis continue to hamper efforts to classify tumours by their patterns of evolutionary development.

Many studies, such as a seminal analysis of 21 breast cancer genomes by Campbell 168 169 and colleagues³⁰, perform bulk sequencing on a single sample and attempt to infer the 170 evolutionary history of the tumour from the variant allelic frequencies (VAF) of somatic 171 mutations. Such studies must attempt to account for variables such as the amount of non-172 tumour tissue sampled, the SCNA profile of the tumour, as well as the accuracy and depth of 173 sequencing, all of which can confound accurate interpretation of the data. Another problem 174 among such studies is sampling bias; a variant may be present in all cancer cells sampled, but 175 not all cancer cells in the tumour (Figure 2). In addition, it may not be possible to distinguish 176 the VAF of mutations within subclones that are the product of selection from those within the VAF distribution 'tail' which is a feature of neutral evolution^{16,31,32}. This tail-like distribution 177 178 of read counts of passenger mutations that are not under selection reflects random 179 mutagenesis at each cell division and the expected relationship between the number of 180 mutational events and their clonal frequency over time.

181 Multi-region sampling, while it does not mitigate against neutral tails, may help to 182 identify and classify subclones more accurately and reduce sampling bias. Nevertheless, this 183 does not represent a 'silver bullet'; typically, only a tiny fraction of the total tumour is 184 assessed³³. Sequencing of every single tumour cell, which remains impossible, would be 185 required to resolve this definitively. Another option is representative sequencing, whereby 186 homogenised fixed tumour material that was not used for pathology is sequenced, thus 187 reducing sampling bias and misclassification rates³³.

Even if clonal sweeps are accurately defined, distinguishing between such an event that may have occurred in the recent past, and one that was present at the inception of the tumour is not always possible. Furthermore, negative selection that has eliminated a clone prior to sampling is not detectable using VAF-based approaches. Therefore, other methods
are required to disentangle the temporal order of events and to distinguish functional events,
subject to selection, from non-functional events, which are not.

Copy-number gains and whole-genome duplication events may be used to time
somatic alterations and separate early from late events occurring during tumour evolution^{29,34}.
In the Pan Cancer Analysis of Whole Genomes (PCAWG), this approach enabled inference
of trends in clonal architecture across tumour types²⁹. In colorectal adenocarcinoma, for
instance, mutations in *APC*, *KRAS* and *TP53* were shown to be predominantly early events,
while certain copy-number alterations including 15q, 21q and 22q loss, were generally late²⁹.

200 A method borrowed from evolutionary biology can provide orthogonal evidence of 201 clonal selection. dN/dS, an assessment of the ratio of substitution rates at nonsynonymous vs. 202 synonymous sites, revealed substantial selection pressures acting on apparently normal tissue³⁵. In cancer, dN/dS has also been used to reveal positive selection globally, and within 203 204 specific cancer genes, as well as a near-absence of negative, or purifying selection³⁶ (Figure 205 3). Whilst dN/dS provides information on global patterns of selection, particularly when large 206 numbers of samples are analysed, it is nevertheless unable to infer selection within specific 207 elements of interest in individual clones (Figure 3C). In addition, further research is needed 208 to enable accurate measurement of selection in the context of other events such as non-coding 209 mutations, indels or structural variants.

Robustly describing tumour evolution with a single binary label, such as neutral or
branched, punctuated or gradual³⁷, remains problematic. Indeed, separate analyses of
identical data can lead to disparate conclusions: a comparison of VAFs in 904 cancers from
14 cancer types, including a minority subjected to multi-region sampling, by Williams and
colleagues suggested that the subclonal VAF distributions in 36% (323/904) of these could be
explained by neutral evolution¹⁶, but subsequent work using an orthogonal approach (dN/dS),
found evidence of subclonal selection within cancer genes in these 323 tumours ^{16,38}.

Single-cell sequencing platforms may provide further insight into tumour evolution 218 (reviewed elsewhere³⁹). This approach presents the opportunity to analyse cellular 219 220 epigenomes, as assessed through DNA methylation, histone configuration or chromatin accessibility, and cell states, inferred from transcriptomic or protein expression data. This 221 222 enables explicit evolutionary context to be added to epigenetic or transcriptomic events. 223 Lineage reconstruction at the single cell level has the potential to improve vastly our 224 understanding of tumour phylogeny. An exemplar of this is Direct Library Preparation single-225 cell whole-genome sequencing, which allows for identification of clonal populations of single cells, pinpointing unique aspects of their genomes⁴⁰. This enables aggregation into 226 227 'pseudo-bulk' samples from which clonal phylogeny may inferred. At present, however, the 228 accuracy of methods to call mutations from typically shallow single-cell sequencing may be 229 limited by PCR errors and allelic dropout. Efforts to resolve this issue will enhance the future 230 success of this approach.

231

232 [H1]Copy-number ITH

233

So far, the main form of variation discussed in this review has been point mutations. However, CIN, and structural variation including SCNAs, whole genome duplication and chromothripsis events may engender large fitness effects. The extent to which CIN provides the substrate for ongoing selection and branched evolution in cancer is unclear. Although CIN has long been linked to poor prognosis⁷, research has only recently explored the question of whether this process continues throughout tumour evolution, or, conversely, whether SCNAs are predominantly relics of past genomic instability. A single-cell study of 12 triple-

- 241 negative breast cancers identified aneuploidy as a punctuated, early event in tumour
- evolution, preceding clonal expansion of a population of cells with a stable karyotype²⁰. This
- 243 finding was supported by recent work on colorectal cancer reported in a preprint; Cross et al
- studied CIN within 755 samples, taken from multiple tumour regions or longitudinally in 167
- 245 patients and found that certain dominant SCNAs were established early in tumour evolution
- and persisted through negative selection of karyotype diversity, in spite of ongoing CIN
 through therapy administration and progression to metastasis⁴¹.
- 248 There are also examples of CIN generating functional events late in tumour evolution. 249 For example, PCAWG demonstrated that chromosomal gains occur throughout 'molecular 250 time', from early human development to the final stages of tumour growth (median molecular 251 time 0.60; IQR 0.10-0.87). However, within certain cancer types such as lung cancer, papillary renal cancer and melanoma, they are predominantly late events²⁹. Furthermore, in a 252 cohort of clear cell renal cell carcinoma (ccRCC), loss of 9p21.3 was subject to subclonal 253 selection and was associated with metastatic progression, as evidenced by the fact that it was 254 a clonal event in just 26% of primary tumour samples versus 64% of metastases ⁴². Late arm-255 256 level SCNAs have also been described in other cancer types^{43–45}.
- 257 Watkins et al. interrogated pan-cancer multi-region data to assess the degree to which 258 CIN provides a substrate for subclonal phenotypic diversification⁴⁶. This work found 259 evidence of parallel evolutionary events, in which the same genes were affected by different 260 subclonal SCNAs in 37% of tumours analysed; examples included gains at 1g21.3-g44 which encompasses BCL9, MCL1 and ARNT, at 5p15.33 which contains TERT, and at 8q24.1 which 261 262 contains MYC. Independent analysis of metastases by multi-region sampling revealed 263 subclonal events within certain tumour types, including gains to MYC in ccRCC and CCND1 264 in *HER2*⁺ breast cancer, which were enriched in metastases relative to primary tumours. 265 Together, this suggests that late in tumour evolution, CIN engenders extensive subclonal 266 diversity. It also expands on *in vitro* work within patient-derived tumour organoids, where 267 ongoing CIN led to karyotypic heterogeneity over time in models of colorectal carcinoma⁴⁷.
- It is likely that, even when looking at the mutation and copy number landscapes in parallel, we still fail to capture events with a large influence on cellular fitness and may draw imperfect conclusions as a result. Extending our focus beyond the genome to the epigenome, transcriptome, and the immune microenvironment may allow us a greater understanding of the true extent of ITH. In this way, we can more accurately define the functional evolutionary processes that influence phenotype (Figure 5).
- 274 275

276 [H1]Epigenetic and transcriptomic ITH277

- Epigenetic dysregulation influences gene expression and is widespread in cancer,
 occurring by varied mechanisms such as promoter hypermethylation, altered enhancer
 activity, and changes in chromatin configuration⁴⁸.
- Alterations to the cancer epigenome can be binary, functioning as 'on or off' 281 282 switches, or induce transient changes in gene expression, forming part of highly plastic gene 283 expression networks. They but can also govern copy number changes. For example, the 284 interplay between lysine demethylases and methyltransferases and their relative activity upon 285 histone H3 lysine 4 (H3K4), H3K9 and H3K27 has been shown to affect copy-number 286 amplification of the EGFR oncogene, which encodes the epidermal growth factor receptor⁴⁹. 287 Dysregulation of the cancer epigenome may be global in some cancers. In a pan-cancer 288 analysis, increased global enhancer expression was seen across multiple cancer types, and 289 enhancer activity correlated with the fraction of the genome affected by SCNAs⁵⁰. This 290 intriguing potential consequence of CIN was posited to relate to its impact on chromatin

state, although the evolutionary context of such epigenomic dysfunction within tumours

requires further elucidation. Interestingly, mutations in genes encoding epigenetic modifiers

alone are sufficient to drive some, and an analysis of 24 types of childhood cancer found this group of genes, including *KMT2C*, *KMT2D* and *SMARCA4*, to be the most commonly

group of genes, including *KMT2C*, *KMT2D* and *SMARCA4*, to be the most commonly
 mutated (mutations in epigenetic modifiers affected 25% of tumours) across all molecular

subtypes⁵¹.

297 Like the epigenome, the cellular transcriptome is frequently aberrant in cancer. 298 Various mechanisms, such as alternate splicing, alternate promoter usage, gene fusions and aberrant oncogenic signalling can underpin this phenomenon $^{52-56}$. The impact of genetic 299 300 alterations on transcription was explored extensively using bulk whole-genome sequencing 301 with matched RNA-sequencing in the recent PCAWG analysis⁵⁵. In this analysis, SCNAs 302 emerged as the dominant genomic event influencing gene expression, contributing to 17% of 303 gene expression variation, compared to somatic and germline genetic variation in *cis*, which 304 contributed to 1.8% and 1.3% respectively. Cumulatively, non-coding mutations contributed more to variation in allelic expression than coding mutations⁵⁵. This underscores the potential 305 problems of restricting focus to exonic mutations, and is supported by our own analysis of 306 307 lists of cancer genes (Figure 4). We compared cancer genes identified by Bailey et al⁵⁷, who systematically catalogued mutations from 9,423 tumour exomes, with those identified in the 308 COSMIC Cancer Gene Census⁵⁸, which incorporates evidence of functional involvement 309 310 alongside increased mutation frequency when curating cancer gene lists. As would be expected, a whole-exome sequencing approach only identifies a subset (330/657) of 311 312 COSMIC cancer genes. Intriguingly, it fails to identify the majority of genes affected by 313 translocations and amplifications (Figure 4A). Greater proportions of the COSMIC cancer 314 genes affecting certain cancer types (BRCA, LGG) are identified by Bailey than others 315 (PAAD, SARC) (Figure 4B). This highlights that many cancer genes are likely undiscovered, 316 a substantial proportion of which may be driven by mechansisms beyond point mutations. 317 For example, RNA variants, generated by editing enzymes, are an additional source of 318 diversity within tumours that impact upon protein function in cancer and would be missed by whole-exome sequencing^{59,60} 319

320 The importance of transcriptomic variation in cancer is underlined by the ability of 321 expression-based biomarkers to predict clinical outcome⁶¹. However, the evolutionary 322 context of this variation is also important: considering ITH in gene expression through multi-323 region bulk RNA-sequencing can significantly improve the predictive ability of such 324 biomarkers. For example, in non-small cell lung cancer (NSCLC), a prognostic gene 325 expression signature calculated from clonally expressed genes reduced the impact of 326 sampling bias, a problem also highlighted by a transcriptomic analysis of multifocal prostate cancer^{62,63}. Multi-region transcriptomics can also shed light on other tumour evolutionary 327 328 processes. Biswas et al underlined the dominant role of SCNAs in influencing gene 329 expression, as ITH of SCNAs was strongly correlated to ITH of gene expression⁶². A multi-330 region transcriptomic analysis of four patients with advanced bladder cancer identified 331 distinct molecular subtypes thought to arise from different urothelial progenitors in distinct 332 regions of the same tumour, suggesting that tumour subtypes may be somewhat plastic rather 333 than entirely pre-determined⁶⁴.

An important caveat for bulk transcriptomic and epigenetic analysis is that such datasets comprise tumour and stromal gene expression which, currently, we can only partly deconvolve; tumour purity may therefore introduce bias into transcriptomic analysis of ITH⁶⁵. Integrated analysis of the genome and transcriptome may help to deconvolve tumourspecific gene expression within bulk sequencing samples⁶⁶.

339 Single-cell sequencing can capture epigenomic and transcriptomic changes and has
 340 helped to shape the concept of cellular transcriptomic promiscuity and its influence on

341 phenotypic plasticity⁶⁷. In lung adenocarcinoma, a highly plastic cellular state is associated

342 with poor prognosis in humans and with treatment resistance in mice; this plastic state

mediates transition to more diverse phenotypes and may explain ITH in some tumours⁶⁸.

344 Jacks and colleagues studied the epigenome of single lung adenocarcinoma cells en route to 345 metastasis and revealed important changes in chromatin state which characterise gradual loss

346 of cellular identity, and may be controlled by key transcription factors such as those of the

347 RUNX family⁶⁹. The identification of a gene expression signature of this subpopulation that

348 associated with survival was particularly intriguing⁶⁹; the ability to robustly obtain from bulk

sequencing evidence of cancer cells with features of stemness, diverse transcriptional
 landscapes and the ability to influence the evolutionary trajectory of a tumour in the presence

351 of selective pressures, would be of great value in both the research and clinical settings.

352 In studies of haematopoiesis, differences in stemness, cellular states, gene expression 353 profiles and enhancer activity have been explicitly linked to mutations in DNA methylation genes, underscoring the importance of these genes in cancer⁷⁰. However, in general, the 354 355 heterogeneity of epigenetic events in human cancers, as well as their interplay with the cancer 356 genome and transcriptome, remains poorly understood. This problem is illustrated by debates 357 surrounding evolutionary trajectories in pancreatic cancer, where genetic driver mutations in 358 TP53, KRAS, CDKN2A or SMAD4, when present, are almost always clonal⁷¹. In isolation, this might indicate an absence of subclonal selection in this disease, but study of the 359 360 epigenome in pancreatic cancer evolution suggests that widespread chromatin remodelling might provide the substrate for selection in metastasis⁷². In chronic lymphocytic leukaemia, 361 the epigenetic landscape is significantly disrupted, driving variety in cellular phenotype, and 362 363 different cancer cell populations may have highly disparate epigenomes⁷³.

364 Hua et al. explicitly compared the ITH of point mutations, SCNAs and DNA methylation in a multi-region study of 84 lung adenocarcinomas⁷⁴. They found that tumour 365 366 evolutionary trees inferred from SCNAs and DNA methylation were highly similar, 367 demonstrating that patterns of cancer evolution may be agnostic of variant mechanism. Congruency of genomic and epigenomic evolution was also recently described in papillary 368 renal cell carcinoma⁷⁵. Future work should seek to devise tools to define more clearly the 369 370 relationship between mutations, CIN and epigenetic and transcriptomic states, in both space 371 and time. Integrating whole-genome sequencing with multi-omics is likely to be important to 372 this endeavour.

373 Ultimately, mutations, SCNAs, epigenetic alterations and transcriptional alterations 374 all influence the abundance, structure and function of proteins, the true arbiters of cellular 375 phenotype. Therefore, proteomic studies may be critical to integrating this information. 376 Moreover, a proteogenomics approach facilitates deep analysis of the impact of functional 377 mutations at the pathway level. Such studies have described novel consequences of mutations 378 and SCNAs in breast cancer⁷⁶, including the identification of alterations in enzymatic activity 379 which were not visible at the transcriptomic level, as well as in gastric and ovarian cancer^{77,78}. In addition, recent publications studying the lung adenocarcinoma proteome with 380 381 mass spectrometry and phosphoproteomics are an important development in this space $^{79-81}$. 382 Proteogenomic analyses have also helped show that the relationship between SCNAs and 383 mRNA and protein abundance may be inconsistent. Intruiguingly, in breast cancer, genes in 384 which a correlation was observed between SCNAs and mRNA as well as between SCNAs 385 and protein levels were more likely to be cancer genes than those without a correlation between SCNAs and protein levels⁷⁶. This suggests that in some settings multi-omic 386 approaches that consider the proteome may be more powerful to detect functional events that 387 388 those that do not. It is hoped that future studies of proteomic ITH, as well as other systems-389 based approaches, will provide insight into functional clonal diversity, and help to resolve 390 long standing debates about cancer biology.

391

392 [H1]Microenvironmental ITH393

A convincing argument to move forward from the reductionist, exclusively genomic, view of tumour evolution stems from the success of immunotherapies that disrupt signalling between cancer and immune cells. If our aim is to understand cancer evolution, we cannot ignore the environment in which a cancer cell evolves. Whether variation is functional or non-functional can be highly context dependent, depending on both the genomic background into which a mutation arises, but also the environment itself. This environmental context has an immune, and a non-immune arm.

401

402 403

[H2] Evolutionary constraints imposed by the anti-tumour immune response

404 A critical component of the tumour microenvironment in a growing cancer is the 405 immune infiltrate. Human cellular biology has evolved to combat the threat of cancer in its 406 tissues through a high-fidelity anti-cancer immune response⁸². A prominent part of this 407 response is the adaptive immune response. Here, a tumour, or its associated non-host peptides 408 (neoantigens) are identified and eliminated through the clonal expansion of a highly specific 409 T-cell population and degradation by cytotoxic CD8+ T-cells, or by a CD4+ T-cell-410 dependent cytotoxic response^{83,8485}.

411 The anti-tumour immune response equates to a clone-specific negative selection 412 pressure and there are a number of mechanisms that cancers can co-opt in order to evade 413 detection and elimination. Many of these are genomic. For example, mutations in beta-2-414 microglobulin, B2M, a component of the Major Histocompatibility Complex, disrupt antigen presentation in response to immune predation⁸⁶. Similarly, cancer cells undergo loss-of-415 416 heterozygosity (LOH) of the Human Leucocyte Antigen (HLA) locus on chromosome 6p. In 417 one study, HLA LOH was detected in 40% of NSCLC and was subclonal in 65% of cases⁸⁷. This finding was supported by a recent pan-cancer analysis of multi-region sampled tumours. 418 419 where 22% of all tumours demonstrated subclonal loss of two copies of the same HLA allele after whole genome doubling⁴⁶. SCNAs outside of the HLA locus can also promote immune 420 evasion, for example through copy-number loss of neoantigens capable of stimulating a 421 422 functional T cell response^{88,89}. In mouse models of ovarian cancer, immune-excluded tumour 423 regions were characterised by copy-number amplification of MYC target genes and increased 424 WNT signalling⁹⁰. An abundance of non-specific SCNAs has also been proposed as a 425 predictor of poor response to immunotherapy⁹¹; however, disentangling their well-described 426 prognostic role from a predictive one is difficult, and requires further study. There is also 427 evidence of transcriptional neoantigen depletion underpinning immune escape. In NSCLC, 428 downregulation of neoantigenic transcripts was found to occur via promoter 429 hypermethylation (seen in 23% of silenced neoantigen-containing genes versus 11% of the 430 same non neoantigen-containing genes) and was enriched in immune-infiltrated tumours with 431 an intact HLA allele, suggestive of diverse cellular responses to the negative selection pressure imposed by the anti-tumour immune response⁸⁹. Indeed, the remaining repressed 432 433 neoantigens not subject to promoter hypermethylation may be affected by mechanisms that 434 are yet to be elucidated.

Not all neoantigens stimulate a uniform anti-tumour immune response, demonstrating
the importance of distinguishing between functional and non-functional ITH. Clonal
neoantigens stimulate anti-tumour immunity, and those tumours containing neoantigenreactive tumour-infiltrating lymphocytes (TILs) are associated with better outcome⁹². In a
multi-region study of NSCLC, Chain and colleagues reported a correlation between the
number of T-cell clones found in all tumour regions, and the number of clonal, but not

441 subclonal mutations, emphasising the importance of neoantigens in stimulating the immune 442 response early in tumour evolution⁹³. Furthermore, the clonality of T-cells within a tumour has also been associated with improved response to anti-programmed cell death 1 (PD1) 443 therapy in melanoma^{94,95}, although other facets of the T-cell repertoire, such as the diversity 444 of circulating T-cell clones in peripheral blood, also impact response to immune checkpoint 445 446 blockade⁹⁶. Importantly, the clonal diversity of neoantigens can also influence the anti-447 tumour immune response. Using an immune-competent mouse model of melanoma, Wolf 448 and colleagues showed a correlation between increased clonal diversity and ineffective rejection of the developing tumour⁹⁷. This builds on earlier findings in mice which suggested 449 450 that the fraction of cells expressing a clonal, immunogenic peptide is key in determining 451 whether a tumour is eliminated, with small subclones being more able to evade immune

452 rejection⁹⁸.

453 As clonal diversity can influence the immune response to a developing tumour, so this 454 response can provide a negative selection pressure on a growing tumour and in turn shape its 455 clonal composition. This is illustrated by recent work in a glioma model, where the immune 456 editing that occurred within immune-competent mice led to the formation of tumours with lower clonality⁹⁹. In high-grade serous ovarian cancer, tumour regions with the highest levels 457 of immune infiltrate were characterised by neoantigen depletion, subclonal HLA LOH, and 458 459 low clone diversity, indicating predation of that region prior to sampling¹⁰⁰. These findings 460 are consistent with a study of metastatic colorectal cancer, where those metastases that persist were the least immunogenic, and harboured diverse mechanisms of immune escape¹⁰¹. 461 462 Negative selection has also been reported prior to formation of an invasive cancer: 463 histopathological and molecular analysis of pre-invasive lung lesions suggested that immune 464 surveillance is more active in those that regress, relative to those that progress to invasive cancer¹⁰². 465

466 The extent to which negative selection pressure is exerted on the developing tumour 467 throughout its evolution is unclear: studies have suggested that neoantigen-encoding mutations may be depleted within primary tumours, indicating the impact of negative 468 selection prior to sampling^{86,91,103}. However, in a recent analysis which adjusted for single 469 470 nucleotide substitution mutational signatures, no evidence of negative selection against neoantigens was found, with the exception of NSCLC¹⁰⁴. A recent preprint reported an 471 472 orthogonal approach, restricting dN/dS to the immunopeptidome, that detected immune selection in some tumours¹⁰⁵. Intriguingly, pre-treatment immune selection was detected at 473 474 increased levels within a subset of patients with metastatic disease who responded poorly to 475 immune checkpoint inhibitor therapy¹⁰⁵.

476 Just as nonsynonymous mutations in a tumour may be immunologically functional or 477 non-functional depending on their ability to elicit a T-cell response, so the functionality and 478 differentiation state of T-cells may also vary between tumours. Work on NSCLC found that 479 dysfunctional and terminally differentiated T-cells expressing PD1 and inducible T-cell 480 costimulatory (ICOS) were more predominant in tumours with a high mutational burden, 481 whilst progenitor-like T-cells in the early stages of differentiation expressing CD27 and 482 CD28, and lacking signs of antigen engagement, were seen in tumours with a low mutational burden¹⁰⁶. This is clinically significant as a gene signature of differentiation skewing was 483 484 associated with a worse prognosis across multiple tumour types without immunotherapy¹⁰⁶.

A structured immune microenvironment, manifest as spatial differences between
areas of the same tumour, can be important to both the trajectory of a tumour and patient
outcome. In triple-negative breast cancer, highly multiplexed imaging enabled classification
of tumours by their extent of tumour-immune mixing, as either 'cold', 'mixed' or
'compartmentalized'¹⁰⁷. Intriguingly, this feature correlated with expression of the
immunotherapy targets indoleamine 2,3-dioxygenase 1 (IDO1) and PD1 ligand 1 (PDL1) on

491 tumour or non-tumour cells: in the compartmentalized tumours, IDO-1 and PDL1 were

- 492 expressed by non-tumour cells, such as monocytes, and these tumours were associated with
- improved prognosis¹⁰⁷. Within lung adenocarcinoma, the presence of more than one 493
- 494 'immune-cold' region in which immune evasion might have occurred, predicted poor patient
- outcome irrespective of the immune phenotypes observed in the rest of the tumour¹⁰⁸. 495
- 496 Immune-cold regions from the same tumour were more likely to share subclonal mutations 497
- than immune-hot regions, raising the possibility that 'functional' events, which mostly 498 remain to be elucidated, underpin the ability of an evolving tumour to evade immune 499 rejection.

500 Taken together, these studies demonstrate that tumours, or parts of tumours, may have 501 different relationships with the anti-tumour immune response and can behave differently, 502 thereby highlighting the importance of heterogeneity in the microenvironment of a tumour 503 towards shaping its evolution.

- 504
- 505 The non-immune microenvironment and tumour evolution
- 506

507 Cancers exploit local signalling networks that can profoundly impact cellular identity, 508 to co-opt stromal cells and foster a microenvironment that is favourable to tumour growth via the angiogenic switch, epithelial-to-mesenchymal transition and other processes (reviewed 509 510 elsewhere¹⁰⁹). This creates regional spatial differences between parts of tumours, which may 511 be observed by analysis of pH gradients, hypoxia and growth factor concentration¹¹⁰. 512 Moreover, ITH may be driven in part by microenvironmental factors: this is supported by 513 modelling data¹¹¹ and implied in a study of ccRCC, where regional variations observed on imaging could not be accounted for by genetic variation¹¹². Interactions between cancer cells 514 515 and their stromal counterparts can profoundly influence the trajectory of a tumour. p53-516 dependent senescence in hepatic stellate cells may act in a non-cell-autonomous manner to 517 promote macrophage differentiation and an anti-tumourigenic microenvironment¹¹³. In 518 contrast, cancer cells may co-opt the systemic environment, outside the confines of the 519 tumour, such as in the formation of the pre-metastatic niche through tumour-secreted factors and tumour-shed vesicles¹¹⁴. Incoming cancer cells can then interact with this environment. 520 521 For example, a co-culture system demonstrated that, in the early stages of lung metastasis, 522 interaction between alveolar epithelial cells and disseminated breast cancer cells has been 523 shown to influence behaviour of metastatic cells, enabling them to remain indolent and 524 survive for long periods of time¹¹⁵.

525 Distinct clones within a tumour may also interact; clonal cooperativity within a cancer has been described in mouse models of breast cancer¹¹⁶. Furthermore, in a study of human 526 527 colorectal cancer tissue, Schurch and colleagues used co-detection by indexing (CODEX) 528 imaging of formalin-fixed, paraffin-embedded tissues to profile the 'cellular

- 529
- neighbourhoods', and found that features of their relationships, such as coupling of the 530 immune and tumour neighbourhoods and disruption of inter-neighbourhood communication, 531 correlated with poor prognosis¹¹⁷.
- 532 Understanding the extent of cooperation and 'task sharing' between cancer clones is 533 an important area of further study. Highly multiplexed imaging modalities such as mass 534 cytometry are increasingly facilitating the accurate phenotyping of diverse cell types obtained 535 from tumour samples. This has given greater granularity to early observations of clonal cooperation, and relationships between cells can be described in detail^{118–120}. Multi-omic 536 studies that can be mapped spatially to the tumour will help to further define functional 537 538 examples of tumour heterogeneity.
- 539

540 **Clinical impact of ITH**

541

542 ITH and assessments of tumour evolutionary trajectories, as well as the interplay 543 between the cancer cell and the immune microenvironment are all important in the context of 544 clinical questions. Will a tumour metastasise? Will it respond to therapy, and how durable 545 will any response be? What is the prognosis of this cancer? In order to answer such questions, 546 we must have as clear a picture as possible of the phenotype of the tumour: for this, we must 547 comprehend the evolutionary forces that have fostered it.

548549 Metastasis

550

551 Understanding functional ITH may provide insights into the process of metastasis. 552 The impact of cancer evolutionary dynamics on metastasis is an active area of research and 553 our current understanding is reviewed elsewhere¹²¹.

Unpaired analysis of genomes from primary and metastatic tumours suggests that 554 metastasis-specific genomically-encoded driver mutations are rare¹²². Nonetheless, the 555 556 abundance of certain driver events in metastases may exceed that within the primary tumour, 557 such as the enrichment for loss of 9p (containing the tumour suppressor CDKN2A), in 558 metastatic ccRCC⁴², or mutations in *MLK4* (also known as *MAP3K21*) pan-cancer¹²². An 559 enrichment within metastatic cancers for mutations of epigenetic regulators has also been 560 characterised, adding weight to the notion that transcriptional promiscuity and phenotypic diversity may be a prerequisite for spread in some settings^{45,72,123}. Importantly, transcriptional 561 promiscuity need not be genomically underpinned, emphasizing the need for analysis beyond 562 563 the metastatic cancer genome.

564 As ITH of primary tumours provides insight into their evolutionary history, so 565 analysis of intra-tumour, and inter-tumour heterogeneity in metastases can shape our 566 understanding of their biology. For example, in using genomics to attempt to understand the timing of metastatic dissemination, an appreciation of genomic heterogeneity within both 567 568 primary tumours and metastases is essential. Under-sampling of a primary tumour may 569 exaggerate the degree of genetic divergence between primary and metastatic lesions and 570 hence convey metastatic divergence occurring earlier in evolutionary time, potentially 571 contributing to a lack of consensus in the field. In a cohort of 17 patients with disseminated 572 breast cancer, metastatic divergence was estimated to occur relatively late, at 87% of molecular time¹²³. Conversely, a recent analysis by Curtis and colleagues, using 573 574 mathematical modelling, estimated metastatic seeding to occur 2-4 years before diagnosis in 575 colorectal, breast and lung cancers¹²⁴. This study also highlighted a role for systemic anti-576 cancer treatment in promoting clonal evolution and thus influencing ITH at relapse: 57% of 577 treated metastases showed private driver events, compared to 20% of those that were 578 untreated. This work also serves to highlight the fact that an as-yet-undefined degree of the 579 genetic diversity demonstrated in other studies of post-therapy tumour metastases may reflect 580 ongoing evolution in response to treatment.

581 The problem with sampling also extends to questions regarding the mode of dissemination to the metastatic site. To robustly assess this, multi-region sampling of both 582 583 primary and metastatic lesions is required, and there are few studies that have done this to 584 date¹²¹. Nonetheless, many studies have attempted to quantify the relative contributions of 585 monoclonal (a single subclone seeds every metastasis) and polyclonal (multiple subclones 586 seed one or more metastases) dissemination in cancer. Of note, Reiter and colleagues 587 performed an analysis of 317 regions from 20 patients across lymph node and distant 588 metastatic sites, to investigate the relative preponderance of metastatic seeding patterns¹²⁵. 589 They identified a higher genetic diversity among lymph node metastases than distant 590 metastases, suggestive of polyclonal seeding patterns and more relaxed selection pressures in 591 lymph node seeding clones relative to distant sites. The potential pitfalls of inferring seeding

- 592 patterns from bulk sequencing is underlined by a study which presents a tool that combines
- inference of clonal lineage with migration histories¹²⁶. By using this tool to re-analyse
- 594 published sequencing data, Raphael and colleagues showed how seeding patterns might often
- be misclassified; for example, in a study that had originally suggested a polyclonal seeding
- 596 pattern, it was posited that monoclonal seeding was in fact a more parsimonious explanation 597 for the data¹²⁶.

598 Whilst multi-region sampling of a resected solid primary tumour is relatively 599 straightforward, ethical constraints prevent simultaneous sampling of multiple metastases 600 from patients. Two strategies that may help to combat this problem and provide insights into 601 the evolutionary history and diversity of cells within the same or different metastases are 602 autopsy studies and circulating tumour DNA (ctDNA) analyses.

603 Autopsy studies allow for sampling of multiple metastases from the same patient. One 604 such study of 76 untreated metastases from 20 patients suggested that driver mutations in this 605 setting are typically found within all metastases and have likely occurred before metastatic dissemination¹²⁷. Another analysis underlined the potential limitations of inferring phylogeny 606 from a single metastatic sample¹²⁸; this revealed pervasive branched evolution in 6 out of 7 607 melanoma patients and suggested that metastases in different sites may have entirely different 608 609 clonal histories, as well as different active mutational processes, than the primary tumour. 610 This is an active area of research and larger autopsy studies, such as the Posthumous Evaluation of Advanced Cancer Environment (PEACE; NCT03004755)¹²⁹, may provide 611 612 greater insights in the future.

613 Studies measuring ctDNA can help to build a picture of functional tumour 614 heterogeneity. In a cohort of 42 patients with gastrointestinal cancers, ctDNA was 615 demonstrated to be superior to a single metastatic biopsy at capturing mechanisms of resistance to targeted therapy in the majority of patients¹³⁰. In one patient where extensive 616 sampling was undertaken following autopsy, parallel mechanisms of resistance had evolved 617 618 across different metastatic sites. This diversity could be captured in ctDNA sampling but 619 would have been missed in any single metastatic biopsy. ctDNA collection can also help to 620 determine the pattern and timing of metastatic spread. In a study of oesophageal adenocarcinoma, extensive sampling, including of the primary tumour, blood plasma and 621 622 metastatic sites at autopsy revealed 'clonal diaspora' as the predominant mode of spread, in which multiple subclones rapidly seeded multiple metastatic sites¹³¹. In studies seeking to 623 624 track pre-defined genetic events over time, targeted panel sequencing of ctDNA represents a 625 promising avenue of research.

626 Immune editing is known to shape the evolution of metastasis in colorectal cancer¹⁰¹, 627 and analysis of a mouse model of breast cancer metastasis by Lo and colleagues suggests the immune-microenvironment can influence the modality of dissemination¹³². In this study, 628 629 dissemination within mice lacking natural killer (NK) cell immunity was more likely to be 630 monoclonal, and cells that spread in clusters had lower expression of NK-activating genes, 631 and increased expression of NK-inhibitory genes. Defining functional ITH in the context of 632 metastasis will be a multi-faceted endeavour that will help to answer outstanding questions 633 about its biology

634

635 [H2]Informing prognosis

636
637 The balance and degree of functional and non-functional ITH within a tumour may
638 have important prognostic implications. ITH of driver mutations, which confer a significant
639 fitness impact upon the cancer cell, could be considered a proxy for 'functional' subclonal
640 diversity. Several studies have described a relationship between clonal diversity of driver

mutations in cancer and poor outcome^{133–138}. In pre-invasive lesions such as Barrett's
esophagus, most measures of clonal genetic diversity have been found to correlate with early
progression to invasive disease¹³⁹. However, the relationship between ITH and outcome is
nuanced. Early acquisition and clonal sweeps of driver events, resulting in a relatively
homogeneous tumour, are also associated with progression to metastasis and poor outcome²³,
as seen in ccRCC⁴².

647 CIN is also a source of functional and non-functional diversity in some tumours, and gene expression correlates of CIN have long been associated with poor outcome across 648 multiple cancer types⁶¹. In NSCLC, subclonal diversity of SCNAs was prospectively 649 650 correlated with poor prognosis, whilst copy number aberrations also conferred poor survival in ccRCC^{45,136}. Conversely, in some settings extreme diversity may be associated with 651 652 improved prognosis. For example, in some malignancies, a high mutational burden may be 653 associated with improved patient outcomes, likely owing to increased immune surveillance^{137,140}. Similarly, patients whose tumours have extreme levels of CIN tend to have 654 better outcomes^{134,141,142}. The fundamental role of CIN in tumourigenesis is underlined by the 655 relative scarcity of SCNAs, when compared to somatic mutations, within normal human 656 657 tissue^{143,144}. Clonal expansion of mutant cells seems seldom to lead to cancer in the absence 658 of SCNAs. A recent study of SCNAs within pre-invasive lesions also highlights their 659 importance: shallow whole-genome sequencing in a longitudinal study of 88 patients with 660 Barrett's esophagus demonstrated that copy-number profiles of lesions were able to predict patients' risk of progression¹⁴⁵. 661

A possible consensus may emerge: ITH of driver events, in the context of tolerable 662 663 amounts of CIN, is associated with poor outcomes in patients (Figure 6). This may result from ongoing subclonal selection of functional variation. However, in the presence of 664 665 extreme CIN, ITH does not predict poor outcome. This paradox may relate to an inability of 666 cells in such tumours to maintain a high-level fitness, or potentially to such tumours being exceptionally susceptible to anti-cancer therapy that may make retaining fitness impossible. 667 668 A recent evolutionary model of the prognostic impact of ITH supports the view that clonal 669 diversity, in the presence of genomic instability, is associated with faster tumour growth and reduced survival for patients¹⁴⁶. 670

671

673

672 [H2]Therapy response and resistance

674 Understanding the clonal architecture of a cancer can be crucial for effective 675 treatment. For example, clonal, rather than subclonal, neoantigens, appear to stimulate an 676 effective immune response, and their abundance has been associated with survival in multiple 677 cohorts treated with immune checkpoint inhibitors^{92,147}. Also, in gastric cancers treated with 678 an experimental fibroblast growth factor receptor (FGFR) inhibitor, response was conditional 679 on a clonal *FGFR2* amplification, and patients with a subclonal amplification failed to 680 respond¹⁴⁸.

Treatment resistance, either de-novo149 or pre-existing, is unfortunately a near-681 ubiquitous feature of cancer treatment. This may arise through varied mechanisms: for 682 example, in NSCLC, patients may develop resistance to first-generation EGFR inhibitors via 683 the EGFR^{T790M} point mutation¹⁵⁰; in glioma, resistance to temozolamide can arise through a 684 fusion structural variant in *MGMT*¹⁵¹; and in acute myeloid leukaemia (AML), transcriptional 685 plasticity may drive resistance to bromodomain and extraterminal (BET) inhibitor therapy¹⁵². 686 687 An understanding of resistance mechanisms may reveal opportunities for further treatment; 688 examples include osimertinib, which binds irreversibly to mutated EGFR-T790M, for 689 treatment of NSCLC, or targeting of enhancer switching with lysine demethylase 1A (KDM1A) inhibition for AML treatment^{150,152}. 690

691 Resistance is rarely attributable to a single event; indeed, extensive CIN, promiscuous

- transcriptional signalling and epigenetic plasticity, all conferring unstable cellular
 phenotypes, may each fuel non-genetic resistance and confound multiple lines of
- treatment^{153–157}. In such circumstances, targeted therapies may have limited value.
- 695 Treatments that co-opt the anti-cancer immune response such as immune checkpoint
- 696 blockade, adoptive T-cell therapy or vaccine therapy, however, might be less vulnerable to
- 697 such resistance. Nevertheless, treatment resistance remains a significant problem^{158,159} and

approaches to delay, or even prevent this are urgently required.

699 Adaptive, evolutionary-aware strategies may hold promise in improving outcomes for 700 patients. Resistant cells can have a relative fitness disadvantage compared to their sensitive neighbours in the absence of treatment $^{160-162}$, and in such a scenario, temporarily withholding 701 702 treatment could cause a net growth in the sensitive population and a decline in the resistant 703 population. Non-destructive modelling, as demonstrated in NSCLC whereby dead cells are 704 collected from culture without disrupting the live population, suggests this approach is effective in controlling the clonal composition of tumours over time¹⁶³. However, preliminary 705 706 results from certain clinical trials of adaptive treatments have been disappointing¹⁶⁴, 707 highlighting the need for further work and a deeper understanding of the fitness costs of 708 resistance and how this can be measured over time.

709

710 [H1] Conclusions and Perspectives711

Our understanding of cancer evolution has increased exponentially in the last decade.
The advent of next-generation sequencing has shed light on extensive genomic heterogeneity
within cancers and given insight into the evolutionary pressures governing tumour growth.

However, it is necessary to acknowledge that further advances in this field will require not only more extensive sampling of the cancer genome across space and time, but also a more in-depth exploration of the cancer cell and its environment, moving beyond the cancer genome. Recent work, analysing the impact of structural variation, epigenomic and transcriptomic dysregulation and the immune microenvironment on cancer evolution have highlighted extensive functional variation within tumours, with profound impacts on phenotype.

723

724 Genetic and non-genetic divergence is a feature of every tumour, in part simply 725 reflecting the random acquisition of mutations during cell division. Thus, rather than simply 726 cataloguing diversity, future work must distinguish between functional and non-functional 727 ITH, identifying events that might be subject to negative or positive selection during tumour 728 evolution. Indeed, this is a fundamental issue for cancer research: notwithstanding the 729 possibility of cure by complete surgical resection of all cancer cells present in a patient, the 730 genetic and non-genetic trajectories of the cells within a tumour have a profound impact on 731 disease prognosis. A thorough understanding of the relative weights exerted by various 732 biological pulleys and levers during this process might enable us to fine-tune anti-cancer 733 treatments and more effectively control the evolutionary fate of cancer cells. 734

735 ToC blurb

736 This review discusses the role of functional (impacting tumour phenotype) and non-

- functional intra-tumour heterogeneity (ITH) in cancer evolution. It highlights the importance
- of considering genetic and non-genetic factors and their impact on patient outcomes.
- 739
- 740

741 Acknowledgements

- 742 The authors would like to thank Chris Bailey, Alex Frankell, Emma Colliver, Carlos-
- 743 Martinez Ruiz and Jonas Demeulemeester for their thoughtful review of the manuscript.
- 744 Figures created with Biorender.com.
- 745

746 **Conflict of Interest**

- 747 The authors declare no conflicts of interest.
- 748 749 **Competing interests**
- The authors declare no competing interests.

Author contributions

750 751 752 753 754 755 756 JRMB and NM both researched data for the article and made a substantial contribution to discussion of content, writing, reviewing and editing the article.

Peer review information

Nature Reviews Cancer thanks Moritz Gerstung and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. 757

758 **Glossary:**

- 759 Chromosomal instability (CIN): A defect in which cells can gain, lose or rearrange parts
- 760 of or whole chromosomes during cell division; this is a source of variation in cancer.
- 761 Chromothripsis: A mutational process in which large numbers of clustered structural
- rearrangements occur in single or multiple chromosomes. 762
- 763 Molecular time: An estimate of the timing of an event, from the first cell division
- 764 following fertilisation to a cell division that occurred only recently before sampling.
- 765 Enhancer: A short genomic region that influences the expression of another gene in *cis*. 766

767

768 References 769

- 770 1. Darwin, C. The origin of species by means of natural selection: or, the preservation of 771 favored races in the struggle for life. (AL Burt New York, 1859).
- 772 Nowell, P. C. The clonal evolution of tumor cell populations. Science 194, 23-28 2. 773 (1976).
- 774 3. Greaves, M. & Maley, C. C. Clonal evolution in cancer. *Nature* **481**, 306–313 (2012).
- 775 Williams, M. J., Werner, B., Graham, T. A. & Sottoriva, A. Functional versus non-4. 776 functional intratumor heterogeneity in cancer. Mol. Cell. Oncol. 3, e1162897 (2016).
- Turajlic, S., Sottoriva, A., Graham, T. & Swanton, C. Resolving genetic heterogeneity 777 5. 778 in cancer. Nat. Rev. Genet. 20, 404-416 (2019).
- 779 6. Marusyk, A., Janiszewska, M. & Polyak, K. Intratumor Heterogeneity: The Rosetta 780 Stone of Therapy Resistance. Cancer Cell 37, 471–484 (2020).
- 781 McGranahan, N., Burrell, R. A., Endesfelder, D., Novelli, M. R. & Swanton, C. 7. 782 Cancer chromosomal instability: therapeutic and diagnostic challenges. *EMBO Rep.* 783 13, 528–538 (2012).
- 784 Alexandrov, L. B. et al. Clock-like mutational processes in human somatic cells. Nat. 8. 785 Genet. 47, 1402–1407 (2015).
- 786 9. Coons, S. W., Johnson, P. C. & Shapiro, J. R. Cytogenetic and Flow Cytometry DNA 787 Analysis of Regional Heterogeneity in a Low Grade Human Glioma. Cancer Res. 55, 1569 LP - 1577 (1995). 788
- 789 10. Teixeira, M. R., Pandis, N., Bardi, G., Andersen, J. A. & Heim, S. Karyotypic 790 Comparisons of Multiple Tumorous and Macroscopically Normal Surrounding Tissue 791 Samples from Patients with Breast Cancer. Cancer Res. 56, 855 LP – 859 (1996).
- 792 11. Navin, N. et al. Inferring tumor progression from genomic heterogeneity. Genome Res.

793		20 , 68–80 (2010).
794	12.	Gerlinger, M. et al. Intratumor Heterogeneity and Branched Evolution Revealed by
795		Multiregion Sequencing. N. Engl. J. Med. 366, 883–892 (2012).
796	13.	OHTA, T. Slightly Deleterious Mutant Substitutions in Evolution. <i>Nature</i> 246, 96–98
797		(1973).
798	14.	Ling, S. <i>et al.</i> Extremely high genetic diversity in a single tumor points to prevalence
799	1.11	of non-Darwinian cell evolution. <i>Proc. Natl. Acad. Sci.</i> 112 , E6496 LP-E6505 (2015).
800	15.	Sottoriva, A. <i>et al.</i> A Big Bang model of human colorectal tumor growth. <i>Nat. Genet.</i>
801	15.	47 , 209–216 (2015).
802	16.	Williams, M. J., Werner, B., Barnes, C. P., Graham, T. A. & Sottoriva, A.
802	10.	Identification of neutral tumor evolution across cancer types. <i>Nat. Genet.</i> 48 , 238–244
804		(2016).
804	17.	Sun, R. <i>et al.</i> Between-region genetic divergence reflects the mode and tempo of
805	17.	tumor evolution. <i>Nat. Genet.</i> 49 , 1015–1024 (2017).
	10	
807	18.	Cross, W. <i>et al.</i> The evolutionary landscape of colorectal tumorigenesis. <i>Nat. Ecol.</i>
808	10	<i>Evol.</i> 2 , 1661–1672 (2018).
809	19.	Baca, S. C. <i>et al.</i> Punctuated Evolution of Prostate Cancer Genomes. <i>Cell</i> 153 , 666–
810	20	677 (2013).
811	20.	Gao, R. <i>et al.</i> Punctuated copy number evolution and clonal stasis in triple-negative
812		breast cancer. Nat. Genet. 48, 1119–1130 (2016).
813	21.	Notta, F. <i>et al.</i> A renewed model of pancreatic cancer evolution based on genomic
814		rearrangement patterns. Nature 538, 378–382 (2016).
815	22.	Field, M. G. et al. Punctuated evolution of canonical genomic aberrations in uveal
816		melanoma. Nat. Commun. 9, 116 (2018).
817	23.	Reiter, J. G. et al. An analysis of genetic heterogeneity in untreated cancers. Nat. Rev.
818		<i>Cancer</i> 639–650 (2019) doi:10.1038/s41568-019-0185-x.
819	24.	Papaemmanuil, E. et al. Clinical and biological implications of driver mutations in
820		myelodysplastic syndromes. <i>Blood</i> 122 , 3616–27; quiz 3699 (2013).
821	25.	Brastianos, P. K. et al. Genomic Characterization of Brain Metastases Reveals
822		Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 5, 1164–1177
823		(2015).
824	26.	Landau, D. A. et al. Mutations driving CLL and their evolution in progression and
825		relapse. Nature 526, 525–530 (2015).
826	27.	Yates, L. R. et al. Subclonal diversification of primary breast cancer revealed by
827		multiregion sequencing. Nat. Med. 21, 751–759 (2015).
828	28.	Mitchell, T. J. et al. Timing the Landmark Events in the Evolution of Clear Cell Renal
829		Cell Cancer: TRACERx Renal. Cell 173, 611-623.e17 (2018).
830	29.	Gerstung, M. et al. The evolutionary history of 2,658 cancers. Nature 578, (2020).
831	30.	Nik-Zainal, S. et al. The life history of 21 breast cancers. Cell 149, 994–1007 (2012).
832	31.	Kessler, D. A. & Levine, H. Large population solution of the stochastic Luria-
833		Delbrück evolution model. Proc. Natl. Acad. Sci. 110, 11682–11687 (2013).
834	32.	Caravagna, G. et al. Subclonal reconstruction of tumors by using machine learning and
835		population genetics. Nat. Genet. 52, 898–907 (2020).
836	33.	Litchfield, K. et al. Representative Sequencing: Unbiased Sampling of Solid Tumor
837		Tissue. Cell Rep. 31, 107550 (2020).
838	34.	Durinck, S. et al. Temporal dissection of tumorigenesis in primary cancers. Cancer
839		Discov. 1, 137–143 (2011).
840	35.	Martincorena, I. et al. High burden and pervasive positive selection of somatic
841		mutations in normal human skin. Science (80). 348, 880–886 (2015).
842	36.	Martincorena, I. et al. Universal Patterns of Selection in Cancer and Somatic Tissues.
	-	

843		<i>Cell</i> 171 , 1029-1041.e21 (2017).
844	37.	McGranahan, N. & Swanton, C. Clonal Heterogeneity and Tumor Evolution: Past,
845		Present, and the Future. Cell 168, 613–628 (2017).
846	38.	Tarabichi, M. et al. Neutral tumor evolution? Nat. Genet. 50, 1630–1633 (2018).
847	39.	Nam, A. S., Chaligne, R. & Landau, D. A. Integrating genetic and non-genetic
848		determinants of cancer evolution by single-cell multi-omics. Nat. Rev. Genet. (2020)
849		doi:10.1038/s41576-020-0265-5.
850	40.	Laks, E. et al. Clonal Decomposition and DNA Replication States Defined by Scaled
851		Single-Cell Genome Sequencing. <i>Cell</i> 179 , 1207-1221.e22 (2019).
852	41.	Cross, W. <i>et al.</i> Stabilising selection causes grossly altered but stable karyotypes in
853		metastatic colorectal cancer. <i>bioRxiv</i> 2020.03.26.007138 (2020)
854		doi:10.1101/2020.03.26.007138.
855	42.	Turajlic, S. <i>et al.</i> Tracking Cancer Evolution Reveals Constrained Routes to
856		Metastases: TRACERx Renal. <i>Cell</i> 173 , 581-594.e12 (2018).
857	43.	Gundem, G. <i>et al.</i> The evolutionary history of lethal metastatic prostate cancer. <i>Nature</i>
858	15.	520 , 353–357 (2015).
859	44.	Suzuki, H. <i>et al.</i> Mutational landscape and clonal architecture in grade II and III
860		gliomas. Nat. Genet. 47, 458–468 (2015).
861	45.	Jamal-Hanjani, M. <i>et al.</i> Tracking the evolution of non-small-cell lung cancer. <i>N. Engl.</i>
862	15.	<i>J. Med.</i> 376 , 2109–2121 (2017).
863	46.	Watkins, T. B. K. <i>et al.</i> Pervasive chromosomal instability and karyotype order in
864	10.	tumour evolution. <i>Nature</i> (2020) doi:10.1038/s41586-020-2698-6.
865	47.	Bolhaqueiro, A. C. F. <i>et al.</i> Ongoing chromosomal instability and karyotype evolution
866	• / •	in human colorectal cancer organoids. <i>Nat. Genet.</i> 51 , 824–834 (2019).
867	48.	Flavahan, W. A., Gaskell, E. & Bernstein, B. E. Epigenetic plasticity and the
868	10.	hallmarks of cancer. Science (80). 357, (2017).
869	49.	Clarke, T. L. <i>et al.</i> Histone Lysine Methylation Dynamics Control EGFR DNA Copy-
870	12.	Number Amplification. <i>Cancer Discov.</i> 10 , 306–325 (2020).
871	50.	Chen, H. <i>et al.</i> A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient
872	50.	Samples. <i>Cell</i> 173 , 386-399.e12 (2018).
873	51.	Gröbner, S. N. <i>et al.</i> The landscape of genomic alterations across childhood cancers.
874	011	<i>Nature</i> 555 , 321–327 (2018).
875	52.	Kahles, A. <i>et al.</i> Comprehensive Analysis of Alternative Splicing Across Tumors from
876	02.	8,705 Patients. <i>Cancer Cell</i> 34 , 211-224.e6 (2018).
877	53.	Shiraishi, Y. <i>et al.</i> A comprehensive characterization of cis-acting splicing-associated
878	001	variants in human cancer. <i>Genome Res.</i> 28, 1111–1125 (2018).
879	54.	Demircioğlu, D. <i>et al.</i> A Pan-cancer Transcriptome Analysis Reveals Pervasive
880	011	Regulation through Alternative Promoters. <i>Cell</i> 178 , 1465-1477.e17 (2019).
881	55.	Calabrese, C. <i>et al.</i> Genomic basis for RNA alterations in cancer. <i>Nature</i> 578 , 129–136
882	001	(2020).
883	56.	Zhang, Y. <i>et al.</i> High-coverage whole-genome analysis of 1220 cancers reveals
884	50.	hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations.
885		Nat. Commun. 11, 736 (2020).
886	57.	Bailey, M. H. <i>et al.</i> Comprehensive Characterization of Cancer Driver Genes and
887	011	Mutations. <i>Cell</i> 173 , 371-385.e18 (2018).
888	58.	Sondka, Z. <i>et al.</i> The COSMIC Cancer Gene Census: describing genetic dysfunction
889	20.	across all human cancers. <i>Nat. Rev. Cancer</i> 18 , 696–705 (2018).
890	59.	Baysal, B. E., Sharma, S., Hashemikhabir, S. & Janga, S. C. RNA Editing in
890	57.	Pathogenesis of Cancer. <i>Cancer Res.</i> 77 , 3733–3739 (2017).
892	60.	Chen, L. <i>et al.</i> Recoding RNA editing of AZIN1 predisposes to hepatocellular
074	00.	chen, 2. et al. Recound Real country of Azira prodisposes to hepatocollular

- 893 carcinoma. *Nat. Med.* **19**, 209–216 (2013).
- 61. Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N. & Szallasi, Z. A signature of
 chromosomal instability inferred from gene expression profiles predicts clinical
 outcome in multiple human cancers. *Nat. Genet.* 38, 1043–1048 (2006).
- 897 62. Biswas, D. *et al.* A clonal expression biomarker associates with lung cancer mortality.
 898 *Nat. Med.* 25, 1540–1548 (2019).
- 899 63. Salami, S. S., Tomlins, S. A. & Palapattu, G. S. Transcriptomic Heterogeneity in 900 Multifocal Prostate Cancer. *JCI* 201, 666–667 (2019).
- 901 64. Thomsen, M. B. H. *et al.* Comprehensive multiregional analysis of molecular
 902 heterogeneity in bladder cancer. *Sci. Rep.* 7, 11702 (2017).
- 903 65. Aran, D., Sirota, M. & Butte, A. J. Systematic pan-cancer analysis of tumour purity.
 904 *Nat. Commun.* 6, 8971 (2015).
- 905 66. Wang, F. *et al.* Integrated transcriptomic–genomic tool Texomer profiles cancer
 906 tissues. *Nat. Methods* 16, 401–404 (2019).
- 907 67. Teschendorff, A. E. & Enver, T. Single-cell entropy for accurate estimation of
 908 differentiation potency from a cell's transcriptome. *Nat. Commun.* 8, 15599 (2017).
- Marjanovic, N. D. *et al.* Emergence of a High-Plasticity Cell State during Lung Cancer
 Evolution. *Cancer Cell* (2020) doi:https://doi.org/10.1016/j.ccell.2020.06.012.
- 69. Lafave, L. M. *et al.* Epigenomic state transitions characterize tumor progression in
 912 lung adenocarcinoma. *Cancer Cell* 212–228 (2020) doi:10.1016/j.ccell.2020.06.006.
- 913 70. Izzo, F. *et al.* DNA methylation disruption reshapes the hematopoietic differentiation
 914 landscape. *Nat. Genet.* 52, 378–387 (2020).
- 915 71. Raphael, B. J. Integrated Genomic Characterization of Pancreatic Ductal
 916 Adenocarcinoma. *Cancer Cell* 32, 185-203.e13 (2017).
- 917 72. McDonald, O. G. *et al.* Epigenomic reprogramming during pancreatic cancer
 918 progression links anabolic glucose metabolism to distant metastasis. *Nat. Genet.* 49, 367–376 (2017).
- 920 73. Pastore, A. *et al.* Corrupted coordination of epigenetic modifications leads to diverging
 921 chromatin states and transcriptional heterogeneity in CLL. *Nat. Commun.* 10, 1874
 922 (2019).
- 923 74. Hua, X. *et al.* Genetic and epigenetic intratumor heterogeneity impacts prognosis of
 924 lung adenocarcinoma. *Nat. Commun.* 2459 (2020) doi:10.1038/s41467-020-16295-5.
- 75. Zhu, B. *et al.* The genomic and epigenomic evolutionary history of papillary renal cell carcinomas. *Nat. Commun.* 11, 3096 (2020).
- 927 76. Mertins, P. *et al.* Proteogenomics connects somatic mutations to signalling in breast cancer. *Nature* 534, 55–62 (2016).
- 929 77. Zhang, H. *et al.* Integrated Proteogenomic Characterization of Human High-Grade
 930 Serous Ovarian Cancer. *Cell* 166, 755–765 (2016).
- 931 78. Mun, D.-G. *et al.* Proteogenomic Characterization of Human Early-Onset Gastric
 932 Cancer. *Cancer Cell* 35, 111-124.e10 (2019).
- 933 79. Chen, Y. J. *et al.* Proteogenomics of Non-smoking Lung Cancer in East Asia
 934 Delineates Molecular Signatures of Pathogenesis and Progression. *Cell* 182, 226935 244.e17 (2020).
- 80. Gillette, M. A. *et al.* Proteogenomic Characterization Reveals Therapeutic
 937 Vulnerabilities in Lung Adenocarcinoma. *Cell* 182, 200-225.e35 (2020).
- 81. Xu, J.-Y. *et al.* Integrative Proteomic Characterization of Human Lung
 Adenocarcinoma. *Cell* 182, 245-261.e17 (2020).
- 82. Hanahan, D. & Weinberg, R. A. Hallmarks of Cancer: The Next Generation. *Cell* 144, 646–674 (2011).
- 942 83. Marty, R. et al. MHC-I Genotype Restricts the Oncogenic Mutational Landscape. Cell

943		171 , 1272-1283.e15 (2017).
944	84.	Marty Pyke, R. et al. Evolutionary Pressure against MHC Class II Binding Cancer
945		Mutations. Cell 175, 416-428.e13 (2018).
946	85.	DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F. & Jacks, T. Expression of
947		tumour-specific antigens underlies cancer immunoediting. <i>Nature</i> 482 , 405–409
948		(2012).
949	86.	Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and
950		Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity. Cell
951		160 , 48–61 (2015).
952	87.	McGranahan, N. et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer
953		Evolution. Cell 171, 1259-1271.e11 (2017).
954	88.	Anagnostou, V. et al. Evolution of neoantigen landscape during immune checkpoint
955		blockade in non-small cell lung cancer. Cancer Discov. 7, 264–276 (2017).
956	89.	Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution.
957		Nature 567, 479–485 (2019).
958	90.	Jiménez-Sánchez, A. et al. Unraveling tumor-immune heterogeneity in advanced
959		ovarian cancer uncovers immunogenic effect of chemotherapy. Nat. Genet. 52, 582-
960		593 (2020).
961	91.	Davoli, T., Uno, H., Wooten, E. C. & Elledge, S. J. Tumor aneuploidy correlates with
962		markers of immune evasion and with reduced response to immunotherapy. Science
963		(80). 355, (2017).
964	92.	McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and
965		sensitivity to immune checkpoint blockade. Science (80). 351, 1463–1470 (2016).
966	93.	Joshi, K. et al. Spatial heterogeneity of the T cell receptor repertoire reflects the
967		mutational landscape in lung cancer. Nat. Med. 25, 1549–1559 (2019).
968	94.	Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4
969		and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med. 9,
970		eaah3560 (2017).
971	95.	Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune
972		resistance. <i>Nature</i> 515 , 568–571 (2014).
973	96.	Snyder, A. et al. Contribution of systemic and somatic factors to clinical response and
974		resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
975		<i>PLOS Med.</i> 14 , e1002309 (2017).
976	97.	Wolf, Y. et al. UVB-Induced Tumor Heterogeneity Diminishes Immune Response in
977		Melanoma. Cell 179, 219-235.e21 (2019).
978	98.	Gejman, R. S. et al. Rejection of immunogenic tumor clones is limited by clonal
979		fraction. <i>Elife</i> 7 , e41090 (2018).
980	99.	Maire, C. L. et al. Glioma escape signature and clonal development under immune
981		pressure. J. Clin. Invest. 130, 5257–5271 (2020).
982	100.	Zhang, A. W. et al. Interfaces of Malignant and Immunologic Clonal Dynamics in
983		Ovarian Cancer. Cell 173, 1755-1769.e22 (2018).
984	101.	Angelova, M. et al. Evolution of Metastases in Space and Time under Immune
985		Selection. Cell 175, 751-765.e16 (2018).
986	102.	Pennycuick, A. et al. Immune surveillance in clinical regression of pre-invasive
987		squamous cell lung cancer. Cancer Discov. CD-19-1366 (2020) doi:10.1158/2159-
988		8290.CD-19-1366.
989	103.	Zapata, L. et al. Negative selection in tumor genome evolution acts on essential
990		cellular functions and the immunopeptidome. Genome Biol. 19, 67 (2018).
991	104.	Eynden, J. Van Den, Jiménez-sánchez, A., Miller, M. L. & Larsson, E. Lack of
992		detectable neoantigen depletion signals in the untreated cancer genome. Nat. Genet.

993		(2019) doi:10.1038/s41588-019-0532-6.
994	105.	Zapata, L. et al. dN/dS dynamics quantify tumour immunogenicity and predict
995		response to immunotherapy. <i>bioRxiv</i> 2020.07.21.215038 (2020)
996		doi:10.1101/2020.07.21.215038.
997	106.	Ghorani, E. et al. The T cell differentiation landscape is shaped by tumour mutations
998		in lung cancer. Nat. Cancer 1, 546–561 (2020).
999	107.	Keren, L. et al. A Structured Tumor-Immune Microenvironment in Triple Negative
1000		Breast Cancer Revealed by Multiplexed Ion Beam Imaging. Cell 174, 1373-1387.e19
1001		(2018).
1002	108.	Abduljabbar, K. et al. Geospatial immune variability illuminates differential evolution
1003		of lung adenocarcinoma. Nat. Med. 26, 1054–1062 (2020).
1004	109.	Wang, M. et al. Role of tumor microenvironment in tumorigenesis. J. Cancer 8, 761–
1005		773 (2017).
1006	110.	Korenchan, D. E. & Flavell, R. R. Spatiotemporal pH Heterogeneity as a Promoter of
1007		Cancer Progression and Therapeutic Resistance. Cancers (Basel). 11, 1026 (2019).
1008	111.	Lloyd, M. C. et al. Darwinian Dynamics of Intratumoral Heterogeneity: Not Solely
1009		Random Mutations but Also Variable Environmental Selection Forces. Cancer Res.
1010		76 , 3136–3144 (2016).
1011	112.	Hoefflin, R. et al. Spatial niche formation but not malignant progression is a driving
1012		force for intratumoural heterogeneity. Nat. Commun. 7, 11845 (2016).
1013	113.	Lujambio, A. et al. Non-Cell-Autonomous Tumor Suppression by p53. Cell 153, 449–
1014		460 (2013).
1015	114.	Peinado, H. et al. Pre-metastatic niches: organ-specific homes for metastases. Nat.
1016		<i>Rev. Cancer</i> 17 , 302–317 (2017).
1017	115.	Montagner, M. et al. Crosstalk with lung epithelial cells regulates Sfrp2-mediated
1018		latency in breast cancer dissemination. <i>Nat. Cell Biol.</i> 22, 289–296 (2020).
1019	116.	Marusyk, A. et al. Non-cell-autonomous driving of tumour growth supports sub-clonal
1020		heterogeneity. <i>Nature</i> 514 , 54–58 (2014).
1021	117.	Schürch, C. M. <i>et al.</i> Coordinated Cellular Neighborhoods Orchestrate Antitumoral
1022	110	Immunity at the Colorectal Cancer Invasive Front. <i>Cell</i> 182 , 1341-1359.e19 (2020).
1023	118.	Wagner, J. <i>et al.</i> A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human
1024	110	Breast Cancer. <i>Cell</i> 177 , 1330-1345.e18 (2019).
1025	119.	Ali, H. R. <i>et al.</i> Imaging mass cytometry and multiplatform genomics define the
1026	100	phenogenomic landscape of breast cancer. <i>Nat. Cancer</i> 1 , 163–175 (2020).
1027	120.	Jackson, H. W. <i>et al.</i> The single-cell pathology landscape of breast cancer. <i>Nature</i> 578 , (15, (20, (2020))
1028	101	615–620 (2020).
1029	121.	Birkbak, N. J. & McGranahan, N. Cancer Genome Evolutionary Trajectories in
1030	100	Metastasis. <i>Cancer Cell</i> 37 , 8–19 (2020).
1031	122.	Priestley, P. <i>et al.</i> Pan-cancer whole-genome analyses of metastatic solid tumours.
1032	102	Nature 575, 210–216 (2019).
1033	123.	Yates, L. R. <i>et al.</i> Genomic Evolution of Breast Cancer Metastasis and Relapse.
1034 1035	124.	Cancer Cell 32 , 169-184.e7 (2017).
1035	124.	Hu, Z., Li, Z., Ma, Z. & Curtis, C. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. <i>Nat. Genet.</i> 52 , 701–708
1030		(2020).
1037	125.	Reiter, J. G. <i>et al.</i> Lymph node metastases develop through a wider evolutionary
1038	123.	bottleneck than distant metastases. <i>Nat. Genet.</i> 52 , 692–700 (2020).
1039	126.	El-Kebir, M., Satas, G. & Raphael, B. J. Inferring parsimonious migration histories for
1040	120.	metastatic cancers. <i>Nat. Genet.</i> 50 , 718–726 (2018).
1041	127.	Reiter, J. G. <i>et al.</i> Minimal functional driver gene heterogeneity among untreated
1074	14/.	rener, v. G. et ut. minimul functional driver gene neurogenenty among unitedicu

1043		metastases. Science 361 , 1033–1037 (2018).
1044	128.	Rabbie, R. et al. Multi-site clonality analysis uncovers pervasive heterogeneity across
1045		melanoma metastases. Nat. Commun. 11, 4306 (2020).
1046	129.	NCT03004755. The PEACE (Posthumous Evaluation of Advanced Cancer
1047		Environment) Study (PEACE). ClinicalTrials.gov
1048		https://clinicaltrials.gov/ct2/show/NCT03004755.
1049	130.	Parikh, A. R. et al. Liquid versus tissue biopsy for detecting acquired resistance and
1050		tumor heterogeneity in gastrointestinal cancers. Nat. Med. 25, 1415–1421 (2019).
1051	131.	Noorani, A. et al. Genomic evidence supports a clonal diaspora model for metastases
1052		of esophageal adenocarcinoma. Nat. Genet. 52, 74-83 (2020).
1053	132.	Lo, H. C. et al. Resistance to natural killer cell immunosurveillance confers a selective
1054		advantage to polyclonal metastasis. Nat. Cancer (2020) doi:10.1038/s43018-020-
1055		0068-9.
1056	133.	Landau, D. A. et al. Evolution and Impact of Subclonal Mutations in Chronic
1057		Lymphocytic Leukemia. Cell 152, 714–726 (2013).
1058	134.	Andor, N. et al. Pan-cancer analysis of the extent and consequences of intratumor
1059		heterogeneity. Nat. Med. 22, 105-113 (2016).
1060	135.	Rye, I. H. et al. Intratumor heterogeneity defines treatment-resistant HER2+ breast
1061		tumors. Mol. Oncol. 12, 1838–1855 (2018).
1062	136.	Turajlic, S. et al. Deterministic Evolutionary Trajectories Influence Primary Tumor
1063		Growth: TRACERx Renal. Cell 173, 595-610.e11 (2018).
1064	137.	Cerrano, M. et al. Prognostic Impact of Clonal Diversity in Acute Myeloid Leukemia
1065		(AML) Treated with Intensive Chemotherapy (IC). Blood 134, 2700 (2019).
1066	138.	Iacobuzio-Donahue, C. A., Litchfield, K. & Swanton, C. Intratumor heterogeneity
1067		reflects clinical disease course. Nat. Cancer 1, 3-6 (2020).
1068	139.	Martinez, P. et al. Dynamic clonal equilibrium and predetermined cancer risk in
1069		Barrett's oesophagus. Nat. Commun. 7, 12158 (2016).
1070	140.	Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental Mechanisms of Immune
1071		Checkpoint Blockade Therapy. Cancer Discov. 8, 1069–1086 (2018).
1072	141.	Birkbak, N. J. et al. Paradoxical relationship between chromosomal instability and
1073		survival outcome in cancer. Cancer Res. 71, 3447–3452 (2011).
1074	142.	Jamal-Hanjani, M. et al. Extreme chromosomal instability forecasts improved outcome
1075		in ER-negative breast cancer: a prospective validation cohort study from the TACT
1076		trial. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 26, 1340–1346 (2015).
1077	143.	Lawson, A. R. J. et al. Extensive heterogeneity in somatic mutation and selection in
1078		the human bladder. <i>Science</i> (80). 370 , 75–82 (2020).
1079	144.	Moore, L. <i>et al.</i> The mutational landscape of normal human endometrial epithelium.
1080		<i>Nature</i> 580 , 640–646 (2020).
1081	145.	Killcoyne, S. <i>et al.</i> Genomic copy number predicts esophageal cancer years before
1082		transformation. Nat. Med. (2020) doi:10.1038/s41591-020-1033-y.
1083	146.	Noble, R. & Burley, J. T. When, why and how tumour clonal diversity predicts
1084		survival. <i>Evol. Appl.</i> 1–11 (2020) doi:10.1111/eva.13057.
1085	147.	Riaz, N. <i>et al.</i> Tumor and Microenvironment Evolution during Immunotherapy with
1086	1.40	Nivolumab. <i>Cell</i> 171 , 934-949.e16 (2017).
1087	148.	Pearson, A. <i>et al.</i> High-Level Clonal FGFR Amplification and Response to FGFR
1088	1.40	Inhibition in a Translational Clinical Trial. <i>Cancer Discov.</i> 6 , 838–851 (2016).
1089	149.	Russo, M. <i>et al.</i> Adaptive mutability of colorectal cancers in response to targeted
1090	150	therapies. <i>Science</i> (80). 366 , 1473–1480 (2019).
1091	150.	Mok, T. S. <i>et al.</i> Osimertinib or platinum-pemetrexed in EGFR T790M-Positive lung
1092		cancer. N. Engl. J. Med. 376, 629–640 (2017).

1093	151.	Oldrini, B. et al. MGMT genomic rearrangements contribute to chemotherapy
1094		resistance in gliomas. Nat. Commun. 11, 3883 (2020).
1095	152.	Bell, C. C. et al. Targeting enhancer switching overcomes non-genetic drug resistance
1096		in acute myeloid leukaemia. Nat. Commun. 10, 2723 (2019).
1097	153.	Fong, C. Y. et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature
1098		525 , 538–542 (2015).
1099	154.	Hinohara, K. et al. KDM5 Histone Demethylase Activity Links Cellular
1100		Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell 34, 939-953.e9
1101		(2018).
1102	155.	McGranahan, N. & Swanton, C. Neoantigen quality, not quantity. Sci. Transl. Med.
1103		11 , eaax7918 (2019).
1104	156.	Rambow, F. et al. Toward Minimal Residual Disease-Directed Therapy in Melanoma.
1105		<i>Cell</i> 174 , 843-855.e19 (2018).
1106	157.	Pleasance, E. et al. Pan-cancer analysis of advanced patient tumors reveals interactions
1107		between therapy and genomic landscapes. Nat. Cancer 1, 452–468 (2020).
1108	158.	Gao, J. et al. Loss of IFN-7 Pathway Genes in Tumor Cells as a Mechanism of
1109		Resistance to Anti-CTLA-4 Therapy. Cell 167, 397-404.e9 (2016).
1110	159.	Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific
1111		therapeutic immunity against cancer. Nature 547, 222–226 (2017).
1112	160.	Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of
1113		colorectal cancer patients. Nat. Med. 21, 795-801 (2015).
1114	161.	Xue, Y. et al. An approach to suppress the evolution of resistance in BRAF(V600E)-
1115		mutant cancer. Nat. Med. 23, 929–937 (2017).
1116	162.	Gopal, P. et al. Clonal selection confers distinct evolutionary trajectories in BRAF-
1117		driven cancers. Nat. Commun. 10, 5143 (2019).
1118	163.	Acar, A. et al. Exploiting evolutionary steering to induce collateral drug sensitivity in
1119		cancer. Nat. Commun. 11, 1923 (2020).
1120	164.	Algazi, A. et al. Abstract CT013: SWOG S1320: Improved progression-free survival
1121		with continuous compared to intermittent dosing with dabrafenib and trametinib in
1122		patients with BRAF mutated melanoma. Cancer Res. 80, CT013 LP-CT013 (2020).
1123		
1124	<u>Highl</u>	ighted Refs (not included in the actual References section because Mendeley deletes
1125	them)	
1126	1.	Williams #15
1127		a. This study demonstrates that a subset of tumours evolve without clear
1128		evidence of subclonal selection
1129	2.	Gerstung #28
1130		a. As part of the Pan Cancer Analysis of Whole Genomes, this study provides an
1131		overview of evolutionary patterns across cancer types, identifying different
1132		driver events that typically occur early or late in cancer.
1133	3.	Watkins #46
1134		a. This multi-region, pan cancer analysis of tumour karyotype uncovers parallel
1135		evolution of events within different subclones in one third of tumours
1136		sampled, and identifies the important role of chromosomal instability in
1137		generating subclonal diversity in cancer.
1138	4.	Calabrese #56
1139		a. This pan-cancer study of paired whole genomes and transcriptomes illustrates
1140		the variety of transcriptomic alterations in cancer, and underlines the influence
1141		of copy number events and non-coding mutations on gene expression.
1142	5.	Marjanovic #67

1143	a. This study of a mouse model of lung adenocarcinoma illustrates that highly
1144	plastic stem-like cells with diverse transcriptional states drive resistance to
1145	therapy and poor clinical outcome.
1146	6. McDonald #70
1147	a. This study of pancreatic cancer is an example of the important potential role of
1148	non-genetic variation in cancer evolution.
1149	7. Rosenthal #87
1150	a. This work highlights the role of immune editing in shaping early cancer
1151	evolution by negative selection, as well as the diversity of mechanisms of
1152	immune evasion.
1153	8. Wolf #95
1154	a. Here, a mouse model of melanoma is used to illustrate that increased clonal
1155	diversity of a developing tumour is associated with evasion of the anti-cancer
1156	immune response
1157	9. Rambow #154
1158	a. This work highlights the role played by stem-like cancer cells in non-genetic
1159	mechanisms of resistance to cancer therapy.
1160	
1161	

Figure 1: Functional and non-functional intra-tumour heterogeneity in tumour evolution




Fig. 1 | **Functional and non-functional intra-tumour heterogeneity in tumour evolution.** The increased rate of phenotypic variation in cancers compared with normal tissues means that new subclones arise and compete. A minority contain a driver event, such as a genetic mutation or copy number alteration, that grants a selective advantage. These subclones may grow at a faster rate than their neighbours and outcompete them in a 'selective sweep'.

Figure 2: Methods of assessing tumour evolution: clonal frequency inference





Fig. 2 | Methods of assessing tumour evolution and clonal frequency inference. Three examples of tumour evolution (left panels), with inferred clonal variant allele frequencies (VAFs) (middle panels) and tumour evolution (right panels). Clusters of mutations are ordered according to VAFs; the clonal cluster contains many high-VAF mutations, whereas the 'neutral tail' (coloured grey) contains mutations with lower VAFs. Interpretation can be confounded by sampling. a I Ongoing subclonal selection leads to formation of subclones (blue/grey, orange and blue). All blue/grey, orange and blue mutations appear clonal within the sample, and so have indistinguishable VAFs. Previous selective sweeps are not distinguishable, and so subclonal selection may not be identified. b | Mutations (orange, green and purple) have different VAFs, so subclones are identifiable. Previous negative selection in this tumour is not identified. c I Tumour evolution is reconstructed relatively accurately, with a previous clonal sweep and neutral ongoing evolution, although previous clonal sweeps that occurred very early are not distinguishable.



subclonal selection




Fig. 3 | Methods of assessing tumour

evolution: dN/dS. a I This method uses the ratio of non- synonymous mutations at non- synonymous sites to synonymous mutations at synonymous sites to infer selection. Ratio of substitution rates at non- synonymous sites versus synonymous sites (dN/dS) > 1 indicates that the rate of nonsynonymous mutations is above the expected background, and signifies positive

selection within a given gene or locus. dN/dS = 1 suggests mutations

in that gene are neutral. dN/dS < 1 suggests negative or purifying selection. This technique works on a cohort level rather

than in individual tumours, and ignores selection due to copy number alterations. b I An example cohort comprising

tumours with varying evolutionary histories. c l dN/dS identifies clonal and subclonal selection of driver events within

cancer genes. However, this approach is unable to infer selection within individual clones, and so the group of tumours

with no subclonal selection is not identified. Previous negative selection is identified, as would be expected within genes essential for cellular function. Passenger mutations are not under positive or negative selection.





Fig. 4 | **Tumour evolution may be incorrectly classified using an exclusively genomic approach.** The evolving tumour acquires traits conveying selective advantages. In this example, subclones arise that contain genetic, epigenetic or transcriptomic alterations that give a selective advantage. The subclone containing an advantageous epigenetic alteration begins a selective sweep of the tumour. The subclone containing a neoantigen that stimulates the anticancer immune response is eliminated by neoantigen- reactive T cells. Here, an exclusively genomic approach would fail to identify all of the functional events shaping the evolution of this tumour.



b Cancer genes identified using whole-exome sequencing mutation-based approach in selected cancer types




Fig. 5 | Comparison of cancer genes defined by the COSMIC Cancer Gene Census and by a systematic pan-cancer whole-exome sequencing mutation-based approach. The COSMIC Cancer Gene Census60 curates lists of 'Tier 1' cancer driver genes that have a cancer- related functional role as well as documented evidence of recurrent cancer- causing mutations, and the types of alteration that affect these genes. a I Chart displaying the alteration types affecting COSMIC (release v90) cancer genes that overlap with cancer genes identified in a systematic mutation- based approach by Bailey et al.59 based on pan- cancer whole- exome sequencing. In this analysis, genes that were rescued following manual curation by Bailey et al.59 were excluded, and only genes listed in COSMIC as affecting cancer types studied by Bailey et al.59 were considered. In some cases, COSMIC cancer genes are included more than once if they are affected by multiple alteration types. n is the number of cancer genes that were identified by the approach of Bailey et al.59, while N is the total number of COSMIC cancer genes. With the whole- exome sequencing mutation- based approach, many COSMIC cancer genes were not identified, in particular, those affected by translocation and amplification. This underlines the importance of the role of cancer genes that are not frequently affected by exonic mutations as functional driver events in cancer. The systemic approach of Bailey et al. identified the majority of genes affected by large deletions; in such genes, there may be functional overlap of deletions and loss- of- function mutations, and so they may be more easily identified as drivers. Clearly, COSMIC lists are not exhaustive, and it is probable that many important driver events have not yet been identified. b I For four selected cancer types included in the analysis by Bailey et al.59, the proportion of COSMIC cancer type- specific driver genes that were identified by a cancer type- specific whole- exome sequencing mutation- based analysis is shown. In the example, breast invasive carcinoma (BRCA) and brain lower grade glioma (LGG) have a relatively large proportion (52% and 50%, respectively) of known cancer type- specific cancer genes identified by the systematic mutation- based approach, whereas in ovarian serous cystadenocarcinoma (OV) and sarcoma (SARC) many known cancer genes are missed (13% and 12% identified, respectively). Cancer genes with translocations and amplifications are frequently missed; in sarcoma, for example, only 1 of 41 COSMIC cancer genes affected by a translocation is identified by Bailey et al.59. Data for each cancer type included in the analysis by Bailey et al. are shown in Supplementary Fig. 1.





Fig. 6 | Prognostic impact of intra-tumour
heterogeneity. The relationship between intratumour heterogeneity (ITH)
and clinical outcome is complex, and is influenced
by the degree of clonal diversity among driver
events within the tumour
as well as the extent of genomic instability.
Hypothesized relationships between ITH of driver
events and clinical outcome
(part a) and between genomic instability and clinical
outcome (part b).



Propotion of COSMIC genes & mutation types identified by Bailey et al per cancer type

Supplementary Figure 1: Extended comparison of mutation types within cancer genes defined by the COSMIC Cancer Gene Census and pan-cancer whole-exome sequencing. For all cancer types included in the analysis of Bailey et al that overlap with those in the COSMIC Cancer Gene Census, the proportion of cancer type-specific cancer genes, affected by certain mutation types, that are identified by a cancer-type specific analysis in Bailey et al is shown. In some cases, genes are included more than once if they can be mutated by multiple mechanisms. The number of samples of each tumour type analysed in Bailey et al is specified.

*Lung NOS & Renal NOS (not otherwise specified) - COSMIC Cancer Gene Census v90 does not specify relevant cancer subtypes studied in Bailey et al (LUAD, LUSC and KIRC, KIRP, KICH respectively); COAD and READ were analysed separately but consensus genes merged.